PMID-22869065 – Tesamorelin Cognitive Function in MCI and Healthy Older Adults
Baker LD, Barsness SM, Borber S, Calahan M, Craft S. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429.
Quick Reference
| Property | Value |
|---|---|
| PMID | 22869065 |
| DOI | 10.1001/archneurol.2012.1970 |
| Year | 2012 |
| Journal | Archives of Neurology |
| Study Type | RCT |
| Evidence Level | I (Oxford CEBM) |
| Sample | n=152 (66 adults with MCI + 86 healthy older adults) |
| Peptide(s) Studied | Tesamorelin |
Key Findings
- Tesamorelin (GHRH) 1 mg/day subcutaneous for 20 weeks improved executive function and verbal memory in both MCI and healthy older adults
- Favorable effects on cognition were observed across multiple neuropsychological measures
- Treatment increased IGF-1 levels, which correlated with cognitive improvements, supporting the GH/IGF-1 axis as a mediator of cognitive function in aging
- Adults with MCI showed cognitive benefits comparable to healthy controls, suggesting the intervention may help preserve function even in early cognitive decline
- The cognitive benefits were most pronounced in executive function domains
- Treatment was well-tolerated in the older adult population with no significant adverse cognitive effects
Study Design
Randomized, double-blind, placebo-controlled trial conducted across multiple sites. 152 adults (66 with amnestic MCI and 86 cognitively healthy) aged 55-87 were randomized to tesamorelin (GHRH analog) 1 mg/day subcutaneous or placebo for 20 weeks. Comprehensive neuropsychological battery administered at baseline and 20 weeks. Primary outcomes included measures of executive function, verbal memory, and processing speed. IGF-1 and other biomarkers were measured to assess mechanistic pathways.
Limitations
- 20-week duration may be insufficient to determine long-term cognitive trajectory effects
- MCI subgroup (n=66) was relatively small for drawing definitive conclusions about disease-modifying potential
- No neuroimaging endpoints to assess structural or functional brain changes
- Study used GHRH (tesamorelin) rather than direct GH administration, so effects are mediated through endogenous GH release which varies by individual
- Long-term safety in elderly population not fully characterized
- No assessment of whether cognitive gains persist after treatment discontinuation
Clinical Relevance
This is a pivotal study linking the GH/IGF-1 axis to cognitive function in aging. The finding that tesamorelin improves cognition in both healthy older adults and those with MCI has significant implications for anti-aging and neuroprotective protocols. It provides a mechanistic rationale for including GH secretagogues in cognitive enhancement strategies and supports the use of tesamorelin beyond its FDA-approved indication for HIV lipodystrophy. The study bridges the gap between GH optimization protocols and cognitive health, relevant to Module 4 (GH Optimization) and Module 7 (Neurological/Cognitive Protocols) of the Academy curriculum.
Related
#research #RCT #evidence-level-I #tesamorelin #cognitive